Chemical Engineering @ChemengFiles.Com

Kraton Polymers LLC announced financial results for the three months ended March 31, 2009. Total operating profit totaled $ 185 million for the three months ended March 31, 2009, representing a decrease of U.S. $ 82 million, or 31%, compared to total operating profit of $ 267 million recorded in the three months ended March 31, 2008.

Profits before interest, taxes, depreciation and amortization (Earnings Before Interest, Taxes, Depreciation and Amortization, EBITDA) declared totaled $ 5 million for the quarter ended March 31, 2009, representing a decrease of U.S. $ 10 million, or 66%, compared to EBITDA of $ 15 million declared for the quarter ended March 31, 2008. The net loss was $ 16 million for the quarter ended March 31, 2009, representing an increase in net loss of $ 7 million compared to net loss of $ 9 million during the same period 2008.

Kraton Polymers LLC announced financial results for the three months ended March 31, 2009. Total operating profit totaled $ 185 million for the three months ended March 31, 2009, representing a decrease of U.S. $ 82 million, or 31%, compared to total operating profit of $ 267 million recorded in the three months ended March 31, 2008.

Profits before interest, taxes, depreciation and amortization (Earnings Before Interest, Taxes, Depreciation and Amortization, EBITDA) declared totaled $ 5 million for the quarter ended March 31, 2009, representing a decrease of U.S. $ 10 million, or 66%, compared to EBITDA of $ 15 million declared for the quarter ended March 31, 2008. The net loss was $ 16 million for the quarter ended March 31, 2009, representing an increase in net loss of $ 7 million compared to net loss of $ 9 million during the same period 2008.

ProFibrix BV, has announced that it has done with the commercial license agreement with Crucell NV for PER.C6 (R), a production platform of single human protein. The platform PER.C6 (R) enables ProFibrix produce a recombinant human fibrinogen levels that support the development and commercial deployment of new products. Fibrinogen is at the heart of all ProFibrix products is an essential part of the mechanism of repair of wounds of nature. The main product of the company, Fibrocaps (TM), is based on a fibrinogen derived from human blood plasma, and is unique in a dry powder form of topical hemostatic that stops acute and severe bleeding during surgery or after a wound trauma. Initially, a recombinant fibrinogen applications will be developed for systemic hemostasis and then to develop products of
tissue repair.

ProFibrix BV, has announced that it has done with the commercial license agreement with Crucell NV for PER.C6 (R), a production platform of single human protein. The platform PER.C6 (R) enables ProFibrix produce a recombinant human fibrinogen levels that support the development and commercial deployment of new products. Fibrinogen is at the heart of all ProFibrix products is an essential part of the mechanism of repair of wounds of nature. The main product of the company, Fibrocaps (TM), is based on a fibrinogen derived from human blood plasma, and is unique in a dry powder form of topical hemostatic that stops acute and severe bleeding during surgery or after a wound trauma. Initially, a recombinant fibrinogen applications will be developed for systemic hemostasis and then to develop products of
tissue repair.

Clinical trials with the experimental drug TGN1412 (wikipedia) produced horrific effects in six patients who was fed in March 2006. The drug is a inmunoregulatory whose use is being investigated for the treatment of B-CLL leukemia and rheumatoid arthritis.

The subjects were immediately after the injection severe pain, swelling and other symptoms and apparently permanent damage to your immune system according to an article in the Sunday Times of July 30, 1930 2006.

Clinical trials with the experimental drug TGN1412 (wikipedia) produced horrific effects in six patients who was fed in March 2006. The drug is a inmunoregulatory whose use is being investigated for the treatment of B-CLL leukemia and rheumatoid arthritis.

The subjects were immediately after the injection severe pain, swelling and other symptoms and apparently permanent damage to your immune system according to an article in the Sunday Times of July 30, 1930 2006.